Multiple readouts, one interpretation
Each is interpretable alone. None is decisive on its own. Generated and interpreted by one team on one site, together they answer the only question that matters at this stage: does this molecule advance.
Methods and platforms
Therapeutic expertise
Oncology and immuno-oncology
validated CDX models, already characterized in-house, enable immediate study initiation without the need for model development.
Neurodegeneration
Successful central nervous system (CNS) drug development depends on demonstrating delivery of the therapeutic modality to the intended neuroanatomical target and quantifying its distribution, target engagement, and pharmacodynamic effects within the CNS.
Immunology, inflammation and metabolic disease
Well-established diet-induced obesity models supporting evaluation of metabolic therapies, target engagement, and translational biomarker responses.
The standard behind the data
All in vivo research at IRBM is conducted within an AAALAC International accredited environment. Accreditation is voluntary and peer-reviewed, awarded only where governance, facilities, and scientific practice exceed regulatory baselines. Today, only about 1,140 organizations in 52 countries hold this accreditation.
For your program, this provides independent, third-party validation that the data informing your critical decisions were generated within a system verified for quality, reproducibility, and ethical conduct, reducing potential concerns during due diligence and regulatory review.
More at AAALAC International and in our accreditation announcement.
- Scientific rigor
- Operational consistency
- Ethical oversight

One program, one team, one site
An integrated scientific framework with in vivo pharmacology at the center of translational insight and decision-making.
Biology
DMPK
Science
Biomarkers
Chemistry
In vivo pharmacologists, DMPK scientists, bioanalysts, discovery biologists, histologists, and medicinal chemists work within the same scientific framework, on a single research site. Exposure, effect, and mechanism are interpreted together rather than reviewed as separate data streams arriving from separate providers.
Our team is industry-trained, with methodologies rooted in IRBM’s heritage as MSD Research Laboratories. A study that must be repeated, particularly once a project reaches the in vivo testing stage, does not just add experimental cost, it can set an entire development timeline back by months. The true cost of choosing the wrong CRO is lost time, and our integrated approach is designed to minimize that risk.
Start where your program is
A single study
A defined model validation
The full in vivo package
Whether supporting a single study or an integrated drug discovery program, we scale with your milestones, providing flexible solutions backed by one aligned scientific team.
Move faster from target to preclinical candidate
IRBM’s Integrated Drug Discovery platform unites chemistry, biology, DMPK, and in vivo pharmacology under one scientific framework so candidates advance through fewer handoffs, stronger data continuity, and better-informed decisions.
Frequently Asked Questions
What should I look for when choosing an in vivo pharmacology partner?
Look beyond the availability of a particular model: a strong in vivo pharmacology partner should combine relevant models, scientific expertise and robust study execution with the ability to connect exposure, target engagement, pharmacodynamic effects, efficacy and tolerability into a meaningful biological interpretation. Data quality and traceability, experienced personnel and high standards of animal welfare are equally important. At IRBM, in vivo pharmacology works alongside DMPK, bioanalysis, discovery biology and translational sciences on a single research site, within an AAALAC International-accredited research environment, supporting integrated, decision-ready data throughout drug discovery.
What are the standard endpoints assessed in in vivo pharmacology studies?
Endpoints are selected according to the biological question and model, but typically include exposure, target engagement, PK/PD relationships, efficacy, tolerability and mechanism of action. Depending on the study, these may be complemented by disease-specific endpoints, longitudinal imaging, pharmacodynamic biomarkers, tissue distribution and histological analyses. At IRBM, these complementary readouts are integrated to provide a coherent view of a molecule’s exposure, biological activity and efficacy, supporting informed decisions on whether and how it should advance.
Is IRBM’s in vivo pharmacology platform AAALAC accredited?
Yes. IRBM holds AAALAC International accreditation, awarded in 2026 following peer-reviewed program assessment and an on-site evaluation by an independent panel. All in vivo research at IRBM is conducted within that accredited environment, and under the governance of an Animal Welfare Body (OPBA) and in full alignment with Directive 2010/63/EU and Italian DL 26/2014.
Are IRBM’s in vivo studies conducted to GLP?
For discovery-stage and candidate-selection studies, IRBM provides a non-GLP in vivo environment that combines the flexibility needed to answer complex scientific questions with the operational rigor expected in drug development. QC-tracked processes and GLP-trained staff help ensure reliable, decision-ready data.
Which oncology models are available at IRBM?
IRBM provides access to more than 50 validated cell-line-derived xenograft (CDX) models, complemented by orthotopic and syngeneic platforms spanning solid tumors, hematologic malignancies, and metastatic disease. Quantitative monitoring of disease progression is enabled through caliper-based tumor measurements and longitudinal IVIS Spectrum imaging, generating robust efficacy data to support candidate selection and development decisions.
Can PK/PD, efficacy and biomarker readouts run within a single program?
Yes. IRBM’s in vivo pharmacology, DMPK, bioanalysis, and discovery biology teams operate within a single scientific framework at one research site, enabling exposure, efficacy, mechanism-of-action, and biomarker data to be generated and interpreted as an integrated dataset rather than assembled across multiple providers.
What quality systems, governance, and facilities support IRBM’s in vivo research?
- Oversight by an Animal Welfare Body (AWB, Organismo per il Benessere Animale, OPBA)
- 3Rs (Replace, Reduce, Refine) applied at study design
- Full alignment with Directive 2010/63/EU and Italian DL 26/2014
- 1,500+ m² (16,000+ ft²) purpose-built facility, including SPF and quarantine areas
- 13 dedicated housing rooms, with closed-bottom enriched IVC caging connected to the building monitoring system
- Dedicated surgery, necropsy and sample-processing areas
- GLP-trained personnel and QC-tracked documentation in a non-GLP environment
Start a conversation.
Great science begins here.



